ArticleFrontiers in immunology2024
Immune response profiling of HERV-W envelope proteins in multiple sclerosis: potential biomarkers for disease progression.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».Reviews in medical virology · 2026Review
- Human endogenous retroviruses antibody signatures in severe asthma phenotypes.Immunologic research · 2026Article
- Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression.Annals of clinical and translational neurology · 2026Article
- Transcriptional landscapes of dengue patients reveal associations between HERV activity and disease severity.NAR molecular medicine · 2026Article
- Airway smooth muscle in asthma: insights from a transcriptomic meta-analysis.ERJ open research · 2026Article
- A phylogeny-guided framework for decoding mechanisms of human endogenous retrovirus regulation in health and disease.bioRxiv : the preprint server for biology · 2026Article
- HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis.Frontiers in immunology · 2026Article
- Alterations of placental HERV expression as a result of gestational COVID-19 disease.Frontiers in microbiology · 2026Article
- Exosomal pHERV-W ENV as a dynamic biomarker for relapse prediction and prognosis in multiple sclerosis.Journal of neuroinflammation · 2025Article
- The Role of Human Endogenous Retroviruses in the Initiation and Progression of Melanoma.Biomedicines · 2025Review
- A Characterization of the Humoral Immune Response to Human Endogenous Retroviruses andPathogens (Basel, Switzerland) · 2025Article
- Immune and vascular modulation by HERVs: the role ofFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The envelope proteins syncytin-1 and pHERV-W from the Human Endogenous Retroviral family 'W' (HERV-W) have been identified as potential risk factors in multiple sclerosis (MS). This study aims to evaluate both humoral and cell-mediated immune response to antigenic peptides derived from these proteins across different clinical forms and inflammatory phases of MS. Methods: Indirect enzyme-linked immunosorbent assay (ELISA) was employed to measure immunoglobulin G (IgG) responses to syncytin-1 Results: MS patients exhibited significantly elevated antibody titers against -pHERV-W Discussion: These findings suggest that the pHERV-W envelope protein could be a valuable biomarker for monitoring peripheral inflammation in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.